Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Descending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
57894-0503-01 57894-0503 Daratumumab and hyaluronidase-fihj (human recombinant) Darzalex Faspro 1800.0 mg/15mL, 4.9 mg/15mL, 18.4 mg/15mL, 30000.0 U/15mL, 13.5 mg/15mL, 6.0 mg/15mL, 735.1 mg/15mL Immunotherapy Monoclonal Antibody CD38 Subcutaneous May 1, 2020 In Use
73776-0001-12 73776-0001 Lifileucel AMTAGVI 72000000000.0 1/500mL Immunotherapy Tumor Infiltrating Lymphocytes (TILs) CD4+T, CD8+T Intravenous Feb. 16, 2024 In Use
57962-0007-12 57962-0007 Ibrutinib Imbruvica 70.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Aug. 24, 2022 In Use
57962-0070-28 57962-0070 Ibrutinib IMBRUVICA 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Dec. 20, 2017 In Use
00003-0524-11 00003-0524 Dasatinib Sprycel 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 27, 2006 In Use
54868-5759-00 54868-5759 Dasatinib Sprycel 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 12, 2007 In Use
24338-0050-08 24338-0050 Carmustine Gliadel 7.7 mg/1 Chemotherapy Alkylating Agent Nitrosourea Intracavitary Dec. 13, 2012 In Use
62856-0177-08 62856-0177 Carmustine implant/ polifeprosan 20, polifeprosan 20 with carmustine implant Gliadel 7.7 mg/1 Chemotherapy Alkylating Agent Nitrosourea Intracavitary In Use
49884-0127-91 49884-0127 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 10, 2019 In Use
00378-3098-85 00378-3098 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 15, 2022 In Use
00078-0620-51 00078-0620 Everolimus Afinitor 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral July 29, 2011 In Use
00078-0620-61 00078-0620 Everolimus Afinitor 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral July 29, 2011 In Use
51991-0823-28 51991-0823 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
51991-0823-33 51991-0823 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
63850-0060-01 63850-0060 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
63850-0060-04 63850-0060 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 26, 2023 In Use
70377-0012-22 70377-0012 Everolimus EVEROLIMUS 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
70377-0012-11 70377-0012 Everolimus EVEROLIMUS 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2023 In Use
00093-7768-24 00093-7768 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 10, 2020 In Use
00054-0497-13 00054-0497 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Feb. 12, 2021 In Use
00054-0497-14 00054-0497 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2020 In Use
51285-0367-01 51285-0367 Methotrexate Trexall 7.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
62935-0756-80 62935-0756 Leuprolide acetate Eligard 7.5 mg/.25mL Hormonal Therapy GnRH Agonist Subcutaneous Nov. 1, 2023 In Use
82737-0073-01 82737-0073 Motixafortide Aphexda 62.0 mg/1.7mL Ancillary Therapy Immunostimulant Stem cell mobilizer Subcutaneous Sept. 8, 2023 In Use
70383-0073-01 70383-0073 MOTIXAFORTIDE ACETATE Aphexda 62.0 mg/1.7mL Ancillary Therapy Immunostimulant Stem cell mobilizer Subcutaneous Sept. 8, 2023 In Use

Found 10,000 results in 4 milliseconds — Export these results